Worldwide Cancer Research Grant for MAASTRO on eradicating hypoxia in esophageal cancer

November 11, 2014

A Worldwide cancer research grant has been obtained to study the efficacy of the hypoxia-activated bioreductive prodrug TH-302 in combination with radiotherapy on esophageal tumors. We will investigate the therapeutic impact of TH-302 on radiotherapy using a panel of human esophageal tumor models, to prove that TH-302 efficacy is dependent on the tumor oxygenation status and we will evaluate the value of non-invasive hypoxia PET imaging to predict TH-302 treatment efficacy. Additionally, the possible short-term and long-term normal tissue toxicity of TH-302 and high-dose irradiation with or without oxygen modification using respectively esophagitis and lung pneumonitis/fibrosis assays will be assessed. We are looking for a junior PostDoc to join our team.


Please reload

Featured Posts

Check out this interview with Maastro Lab group leader Marc Vooijs on their recent work on using lipid lowering drugs to reduce Oxygen consumption in...

Lipid Lowering drugs to improve radiotherapy

May 1, 2017

Please reload

Recent Posts
Please reload

Search By Tags
Please reload

Please reload

Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

Copyright © 2020 | Maastricht Radiation Oncology Lab Maastricht University / MUMC

  • Google Places Social Icon
  • Facebook Social Icon
  • Twitter Social Icon